The role of antiangiogenesis therapy: Bevacizumab and beyond

Clinical and Translational Oncology

Volumn 11, Issue 6, 2009, Pages 349-355

  Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Metastasis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; DRUG DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; FORECASTING; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; INDOLES; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73349110096     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0368-0     Document Type: Article

References (74)

1. Winer EP, Morrow M, Osborne CK, Harris JR (2001) Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, pp 651-717.
2. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410. (Pubitemid 37328844)
3. Marty M, Pivot X (2008) The potential of anti- vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 44:912-920.
4. Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29:3-9.
5. Achen MG, Stacker SA (1998) The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int J Exp Pathol 79:255-265. (Pubitemid 28481534)
6. Gerwins P, Skoldenberg E, Claesson-Welsh L (2000) Function of fi broblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34:185-194. (Pubitemid 30320963)
7. Houck KA, Ferrara N, Winer J et al (1991) The vascular endothelial growth factor family: identifi cation of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
8. Tischer E, Mitchell R, Hartman T et al (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947- 11954.
9. Ferrara N (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794-814. (Pubitemid 29411709)
10. Tuder RM, Flook BE, Voelkel NF (1995) Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95:1798-1807.
11. Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530. (Pubitemid 27527914)
12. Ikeda E, Achen MG, Breier G, Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761-19766.
13. Rak J, Mitsuhashi Y, Bayko L et al (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580.
14. Bouvet M, Ellis LM, Nishizaki M et al (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58:2288-2292. (Pubitemid 28252680)
15. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674. (Pubitemid 27193480)
16. de Vries C, Escobedo JA, Ueno H et al (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991.
17. Terman BI, Dougher-Vermazen M, Carrion ME et al (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586.
18. Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164:491-502.
19. Borgstrom P, Gold DP, Hillan KJ, Ferrara N (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203-4214.
20. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844. (Pubitemid 23132159)
21. von Marschall Z, Cramer T, Hocker M et al (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119:1358-1372.
22. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z (2001) The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 10:339-356. (Pubitemid 32472534)
23. Gabrilovich D, Ishida T, Oyama T et al (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150-4166. (Pubitemid 28544331)
24. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
25. Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35-52. (Pubitemid 38821812)
26. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147. (Pubitemid 38524883)
27. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989. (Pubitemid 32937367)
28. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62. (Pubitemid 40093472)
29. Wildiers H, Guetens G, De Boeck G et al (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986. (Pubitemid 36829677)
30. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102-111. (Pubitemid 40127638)
31. Osusky KL, Hallahan DE, Fu A et al (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7:225-233.
32. Vosseler S, Mirancea N, Bohlen P et al (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65:1294-1305. (Pubitemid 40270156)
33. Brown LF, Berse B, Jackman RW et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91.
34. Gasparini G, Toi M, Gion M et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147. (Pubitemid 27034790)
35. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335-2342. (Pubitemid 38702844)
36. Giantonio BJ, Meropol NJ, Catalano PJ et al (2007) Magnitude of progression-free survival improvement and treatment duration in metastatic colorectal cancer (mRC) for bevacizumab in combination with oxaliplatin- containing regimens: an analysis of two phase III studies. J Clin Oncol 25[SUPPL. 18]:4073.
37. Cassidy J, Cunningham D, Berry SR et al (2008) Surgery with curative intent in patients treated with first line chemotherapy + bevacizumab for metastatic colorectal cancer (mCRC): first BEAT and NO 16966. J Clin Oncol 26[SUPPL. 15]: Abstract 4022.
38. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fl uorouracil/folinic acid plus oxaliplatin (FOLFOX- 4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720-1726.
39. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression Is associated a with prolonged overall survival in metastatic colorectal cancer (BRiTE Study). J Clin Oncol 26:5326-5334.
40. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799. (Pubitemid 46224178)
41. Miller KD, Wang M, Gralow J et al (2007) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab of first-line therapy for locally recurrent metastatic breast cancer. N Engl J Med 357:2666-2676.
42. Milles D, Chang A, Romieu G et al (2008) Randomized, double-blind, placebo-controlled phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26[SUPPL. 15]: Abstract LBA1011.
43. Sandler A, Gray R, Perry M et al (2006) Paclitaxel- carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med 355:2542-2550. (Pubitemid 44917502)
44. Manegold C, Von Pawel J, Zatluokal P et al (2007) Randomized, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non small-cell lung cancer. J Clin Oncol 25[SUPPL.]:S388 (Abst LBA 7514).
45. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 349:427-434. (Pubitemid 36910021)
46. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103-2111. (Pubitemid 350296300)
47. Escudier BJ, Ravaud A, Négrier S et al (2008) Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol 26[SUPPL.]:Abstract 5025.
48. Monk BJ, Han E, Josephs-Cowan CA et al (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102:140-144. (Pubitemid 44056265)
49. Burger RA, Sill MW, Monk BW et al (2007) Phase II trial of bevacizumab in persistentor recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171. (Pubitemid 350237599)
50. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum resistant ovarian cancer or peritoneal cancer. J Clin Oncol 25:5180-5186. (Pubitemid 350232248)
51. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol 26:76-81.
52. Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25:5150-5152. (Pubitemid 350232243)
53. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729. (Pubitemid 350086473)
54. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787.
55. Maron R, Vredenburgh JJ, Desjardins A et al (2008) Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol 26[SUPPL.]:Abstract 2074.
56. Malka D, Dromain C, Farace F et al (2007) Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 25[SUPPL.]:4570.
57. D'Adamo D, Anderson S, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142.
58. Fujita K, Sano D, Kimura M et al (2007) Antitumor effects of bevacizumab with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 18:47-51.
59. Kulke MH (2008) Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res 2:152-153.
60. Rini BI (2006) Sorafenib. Exp Opin Pharmacother 7:453-461. (Pubitemid 43379611)
61. Ratain MJ, Eisen T, Stadler WM (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512. (Pubitemid 46630627)
62. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 356:125-134. (Pubitemid 46089673)
63. Bukowski RM, Eisen T, Szczylik C et al (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25[SUPPL.]:Abstract 5023.
64. Llovet J, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 25:Abstract LBA1.
65. Azad N, Annunziata X, Perroy A et al (2008) Combination anti-angiogenesis therapy with sorafenib and bevacizumab in advanced solid tumors. Proceedings TAT 2008, plenary lecture 3, Bethesda, MD, March 20-22, 2008.
66. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24. (Pubitemid 46630489)
67. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896. (Pubitemid 350002890)
68. Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524. (Pubitemid 43854967)
69. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal- cell carcinoma. N Engl J Med 356:115-124. (Pubitemid 46089672)
70. George DJ, Michaelson MD, Rosenberg JE et al (2007) Phase II trial of sunitinib in bevacizumab- refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25[SUPPL.]:Abstract 5053.
71. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348. (Pubitemid 38579480)
72. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964. (Pubitemid 46606209)
73. Kim WY, Kaelin WG Jr (2006) Molecular pathways in renal cell carcinoma: rationale for targeted treatment. Semin Oncol 33:588-595. (Pubitemid 44511973)
74. Muggia F (2008) Critical appraisal of antiangiogenesis: building on our successes. ESOC-5 Proceedings, Abs 7, The Oncologist.com.